-
公开(公告)号：EP2501381B1
公开(公告)日：2017-07-26
申请号：EP10832058.1
申请日：2010-11-16
申请人： Huya Bioscience International LLC , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： ELLIOT, Gary, T. , WANG, Yiping , BAI, Donglu
IPC分类号： A61K31/4025 , A61K31/402 , A61K31/40 , A61K9/22 , A61K9/20 , A61K9/08 , A61P9/00 , A61P9/06 , A61K31/18
CPC分类号： A61K31/4025 , A61K31/18 , A61P9/00 , A61P9/06
摘要： Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 muM to about 20 muM.
摘要翻译： 通过给患有或有患AF风险的受试者施用由一定量的活性剂组成的组合物来治疗或预防心房纤维性颤动（AF），所述活性剂是4-甲氧基-N-（3,5-二 - （1-吡咯烷基）-4-羟基苄基）苯磺酰胺（磺草胺）或其药学上可接受的盐，使得受试者中活性剂的C max值在约1μM至约20μM的范围内。
-
公开(公告)号：EP2655390B1
公开(公告)日：2019-03-27
申请号：EP11851169.0
申请日：2011-12-21
-
公开(公告)号：EP3917921A1
公开(公告)日：2021-12-08
申请号：EP20707973.2
申请日：2020-01-28
发明人： ROMANO, Suzanne, J. , REECE, Hayley, Ann , BENSON, Joseph, Edward Gordon , COLLINS, Sarah , ELLIOTT, Gary T. , GILLINGS, Mireille , GOODENOW, Robert , TYREE, Curtis
IPC分类号： C07D403/10 , A61K31/402 , A61P9/00
-
公开(公告)号：EP2501380B1
公开(公告)日：2016-01-27
申请号：EP10832056.5
申请日：2010-11-16
申请人： Huya Bioscience International LLC , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： ELLIOTT, Gary, T. , WANG, Yiping , BAI, Donglu
IPC分类号： A61K31/4025 , A61K31/402 , A61K31/40 , A61K9/22 , A61K9/20 , A61K9/08 , A61P9/00 , A61P9/06 , A61K9/00
CPC分类号： A61K31/4025 , A61K9/0019
-
公开(公告)号：EP2501380A2
公开(公告)日：2012-09-26
申请号：EP10832056.5
申请日：2010-11-16
发明人： ELLIOTT, Gary, T.
IPC分类号： A61K31/402 , A61K9/22 , A61K9/20 , A61P9/00 , A61P9/04
CPC分类号： A61K31/4025 , A61K9/0019
摘要： A composition comprised of an active agent that is 4-methoxy-N-(3,5-bis-(l- pyrrolidinyl)-4-hydroxy benzyl) benzene sulfonamide or a pharmaceutically acceptable salt thereof is intravenously administered to a subject, substantially evenly over a period of greater than about 15 minutes, to avoid disadvantageous hemodynamic effects, including systemic diastolic and systolic hypotension, to can occur with rapid intravenous or even short-term infusion administration of the active agent.
-
公开(公告)号：EP3454843A1
公开(公告)日：2019-03-20
申请号：EP17796856.7
申请日：2017-05-11
-
公开(公告)号：EP3311810A1
公开(公告)日：2018-04-25
申请号：EP17182709.0
申请日：2010-11-16
申请人： Huya Bioscience International LLC , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： ELLIOT, Gary, T. , WANG, Yiping , BAI, Donglu
IPC分类号： A61K31/4025 , A61K31/402 , A61K31/40 , A61K9/22 , A61K9/20 , A61K9/08 , A61P9/00 , A61P9/06 , A61K31/18
CPC分类号： A61K31/4025 , A61K31/18 , A61P9/00 , A61P9/06
摘要： Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl) benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 µM to about 20 µM.
摘要翻译： 通过给患有或有患AF风险的受试者施用由一定量的活性剂组成的组合物来治疗或预防心房纤维性颤动（AF），所述活性剂是4-甲氧基-N-（3,5-二 - （1-吡咯烷基）-4-羟基苄基）苯磺酰胺（磺草胺）或其药学上可接受的盐，使得受试者中活性剂的C max值在约1μM至约20μM的范围内。
-
公开(公告)号：EP2655390A2
公开(公告)日：2013-10-30
申请号：EP11851169.0
申请日：2011-12-21
发明人： KYAS, Andreas , FREUND, Ernst , SCHLÖRKE, Oliver , PATERNITI, James, R. , ELLIOTT, Gary , LILL, Jorg , ROGALL, Lars , MENIA, Dario
CPC分类号： C07C62/32 , A61K36/73 , A61K2236/333 , C07H1/08 , C07H13/08 , C07H15/24 , C07J63/008
摘要： A cardiogenin major isomer is obtained from a methanol extract of
Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).-
公开(公告)号：EP2501381A2
公开(公告)日：2012-09-26
申请号：EP10832058.1
申请日：2010-11-16
发明人： ELLIOT, Gary, T.
CPC分类号： A61K31/4025 , A61K31/18 , A61P9/00 , A61P9/06
摘要： Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 muM to about 20 muM.
-
公开(公告)号：EP3893870A1
公开(公告)日：2021-10-20
申请号：EP19836740.1
申请日：2019-12-12
IPC分类号： A61K31/4025 , A61P9/06
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.015 秒)
